塞栓療法市場- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年製品別、適応症別、手技別、エンドユーザー別、地域別、競合

世界の塞栓療法市場は、2022年に36億7,000万米ドルと評価され、予測期間には大幅な成長が見込まれ、年間平均成長率（CAGR）は8.35％で、2028年までには59億9,000万米ドルに達する見込みです。

特定の部位への血流を選択的に制限する低侵襲治療である塞栓療法は、世界的に認知度と人気が高まっています。この血管内治療法は、異常な血管を閉塞させ、出血を効果的に抑制したり止血したりするために利用されます。緊急の大出血の場合、特に塞栓療法は侵襲的な手術に代わる実行可能な選択肢として台頭してきています。インターベンショナル・ラジオロジストは様々な臨床現場でこの治療を行っています。特に前立腺肥大症に対する前立腺動脈塞栓術（PAE）や体重減少に対する胃動脈塞栓術（GAE）のような最先端の手技では、塞栓療法の応用範囲は大きく広がっています。これらの手技は、それぞれの疾患の治療に有効であることが証明されています。例えば、PAEは前立腺肥大症による下部尿路症状（LUTS）に対処するために世界的に行われており、年間800件以上の手術が行われています。塞栓療法はまた、慢性疼痛管理、子宮筋腫の治療、肝臓がんなど特定の種類のがんへの対処にも用いられています。

主な市場促進要因

対象患者数の増加

心血管疾患（CVD）の蔓延と治療成功の重要性の高まりにより、効果的な介入策の研究に注目が集まっています。末梢血管疾患は2017年に世界で2億人以上が罹患しました。加齢に伴い、これらの疾患の有病率は上昇し、特に80歳以上の高齢者において顕著です。塞栓療法装置の需要は、その成功率、術後合併症の少なさ、肝臓がんや肝細胞がんのような疾患の発生率の上昇によって牽引されています。肝臓がんは男女ともに最も一般的ながんのひとつであり、2018年には世界で84万人以上が新たに診断されました。腎臓がんの罹患率も、特に英国で増加しています。これらの動向が塞栓療法の需要に寄与しています。

低侵襲手技に対する患者の嗜好の高まり

低侵襲手術への嗜好の高まりが、塞栓療法のような手技の需要を促進しています。患者は、術後の痛みの軽減、合併症の減少、入院期間の短縮、回復時間の短縮などの理由から、これらの手技を選択します。経動脈的化学塞栓療法（TACE）のような手技は低侵襲の選択肢として進化しており、肝細胞がんなどの治療に革命をもたらしています。前立腺動脈塞栓術（PAE）は、前立腺肥大症（BPH）とそれに伴う症状に対する低侵襲的治療法です。これらの治療に対する嗜好の高まりが塞栓療法市場を拡大しています。

政府と民間組織別資金調達と投資

十分な資金と投資は、塞栓療法のような医療処置の研究、開発、改良を促進します。肯定的な試験結果は、医療専門家や患者に信頼を与え、採用需要を促進します。研修プログラムや医学教育が専門家の間で知識を広め、需要の増加につながります。政府の資金援助や支援は保険適用や償還政策に影響を与え、塞栓療法をより身近なものにします。

塞栓療法装置の技術的進歩

塞栓療法装置の技術的進歩は、精度、有効性、低侵襲性を向上させています。強化されたマイクロカテーテル、高度な画像技術、ナビゲーションシステム、ロボット工学、および可視化ツールはこの分野に変革をもたらしました。これらの進歩は、治療成績、患者の安全性、回復時間を向上させています。技術が進化するにつれて、塞栓療法の分野では、これらの手技を強化するさらなる技術革新が見られるようになると思われます。

主な市場課題

厳しい規制

人工塞栓装置は医療機器に分類され、厳しい規制の対象となります。規制の分類は機器の承認や認可に影響し、市場情勢に影響を与えます。

熟練医療従事者の不足

熟練した専門家の不足は、塞栓療法へのアクセスを制限し、患者の転帰に影響を与え、リスクを増大させる。

主要市場動向

買収と共同研究の増加

共同研究により、塞栓療法の研究開発、アクセシビリティ、認知度が向上しています。共同研究は、多様な患者のニーズに合わせた技術革新とソリューションを加速します。

腫瘍学の進歩

革新的ながん治療へのニーズは、塞栓療法のような個別化されたソリューションへの需要を促進します。高精度と最小限の侵襲性により、塞栓療法は個別化されたがん治療において魅力的なものとなっています。

セグメント別インサイト

製品別インサイト

塞栓剤セグメントは、特に肝細胞がん治療において、微小球を必要とする病態の有病率の増加により、市場を独占しています。

エンドユーザー洞察

塞栓療法装置の主要ユーザーは病院です。低侵襲手技の利用の増加、医療提供者の購買力の増加、償還金の利用可能性がこのセグメントの成長に寄与しています。

地域別インサイト

北米

北米は、塞栓療法を必要とする疾患の流行、確立されたヘルスケアシステム、塞栓剤の継続的な進歩により、市場をリードしています。

アジア太平洋

アジア太平洋地域は、患者数の増加、政府のヘルスケア投資、がん罹患率の上昇により、最も急速な成長が見込まれています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（塞栓剤、マイクロカテーテル）
  • 適応症別（腫瘍、血管、動脈瘤、泌尿器科、腎臓内科）
  • 手技別（TACE、TARE）
  • エンドユーザー別（病院、クリニック、外来手術センター）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 北米の塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 手技別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 手技別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 手技別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 手技別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの塞栓療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 適応症別
  • 手技別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 世界の経口臨床栄養市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Business Overview
• Service Offerings
• Recent Developments
• Key Personnel
• SWOT Analysis
  • Medtronic, PLC
  • Microport Scientific
  • Boston Scientific Corporation
  • Stryker
  • Terumo Corporation
  • Penumbra, Inc.
  • Sirtex（CDH）
  • Johnson & Johnson
  • Abbott Laboratories
  • Balt Group

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Embolotherapy Market was valued at USD 3.67 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a Compound Annual Growth Rate (CAGR) of 8.35% and expected to reach USD 5.99 Billion through 2028. Embolotherapy, a minimally invasive treatment that selectively restricts blood flow to specific areas, is gaining recognition and popularity globally. This endovascular procedure is utilized to occlude abnormal blood vessels, effectively controlling or stopping bleeding. In urgent cases of severe hemorrhage, Embolotherapy is emerging as a viable alternative to invasive surgery, particularly for cases like severe bleeding. Interventional radiologists perform this procedure in various clinical settings. The applications of Embolotherapy have expanded significantly, especially in cutting-edge procedures like prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. These procedures have proven to be effective in treating their respective conditions. For instance, PAE is performed globally to address lower urinary tract symptoms (LUTS) caused by BPH, with over 800 procedures annually. Embolotherapy is also used in managing chronic pain conditions, treating uterine fibroids, and addressing specific types of cancer, such as liver cancer.

Key Market Drivers

Growing Target Patient Population

The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.

Rising Patient Preference for Minimally Invasive Procedures

The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.

Funding & Investments by Government and Private Organizations

Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.

Technological Advancements in Embolotherapy Devices

Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.

Key Market Challenges

Stringent Regulations

Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.

Lack Of Skilled Medical Professionals

A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.

Key Market Trends

Increasing Acquisitions and Collaborations

Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.

Advancement in Oncology

The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.

Segmental Insights

Product Insights

The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.

End User Insights

Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.

Regional Insights

North America

North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.

Asia-Pacific

The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.

Key Market Players

• Medtronic, PLC
• Microport Scientific
• Boston Scientific Corporation
• Stryker
• Terumo Corporation
• Penumbra, Inc.
• Sirtex (CDH)
• Johnson & Johnson
• Abbott Laboratories
• Balt Group

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Embolotherapy Market, By Product:

• Embolic Agents
• Microspheres
• Liquid Embolic Agents
• Coil
• Microcatheters

Embolotherapy Market, By Indication:

• Oncology
• Vascular
• Aneurysm
• Urology
• Nephrology

Embolotherapy Market, By Procedure:

• TACE
• TARE

Embolotherapy Market, By End User:

• Hospital
• Clinics
• Ambulatory Surgery Centres

Embolotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

• Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Embolic Agents, Microcatheters)
    • 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
  • 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
  • 5.2.3. By Procedure (TACE, TARE)
  • 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Embolotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
    • 6.2.1.1. By Embolic Agents
  • 6.2.2. By Indication
  • 6.2.3. By Procedure
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Embolotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.1.1. By Embolic Agents
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Procedure
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Embolotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.1.1. By Embolic Agents
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Procedure
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Embolotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.1.1. By Embolic Agents
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Procedure
      • 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
    • 7.2.1.1. By Embolic Agents
  • 7.2.2. By Indication
  • 7.2.3. By Procedure
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Embolotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.1.1. By Embolic Agents
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Procedure
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Embolotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.1.1. By Embolic Agents
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Procedure
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Embolotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.1.1. By Embolic Agents
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Procedure
      • 7.3.3.2.4. By End User
  • 7.3.4. France Embolotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.1.1. By Embolic Agents
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Procedure
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Embolotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.1.1. By Embolic Agents
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Procedure
      • 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
    • 8.2.1.1. By Embolic Agents
  • 8.2.2. By Indication
  • 8.2.3. By Procedure
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Embolotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.1.1. By Embolic Agents
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Procedure
      • 8.3.1.2.4. By End User
  • 8.3.2. India Embolotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.1.1. By Embolic Agents
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Procedure
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Embolotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.1.1. By Embolic Agents
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Procedure
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Embolotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.1.1. By Embolic Agents
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Procedure
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Embolotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.1.1. By Embolic Agents
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Procedure
      • 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
    • 9.2.1.1. By Embolic Agents
  • 9.2.2. By Indication
  • 9.2.3. By Procedure
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Embolotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.1.1. By Embolic Agents
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Procedure
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Embolotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.1.1. By Embolic Agents
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Procedure
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Embolotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.1.1. By Embolic Agents
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Procedure
      • 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
    • 10.2.1.1. By Embolic Agents
  • 10.2.2. By Indication
  • 10.2.3. By Procedure
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Embolotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.1.1. By Embolic Agents
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Procedure
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Embolotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.1.1. By Embolic Agents
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Procedure
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Embolotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.1.1. By Embolic Agents
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Procedure
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Oral Clinical Nutrition Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Service Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Medtronic, PLC
  • 15.5.2. Microport Scientific
  • 15.5.3. Boston Scientific Corporation
  • 15.5.4. Stryker
  • 15.5.5. Terumo Corporation
  • 15.5.6. Penumbra, Inc.
  • 15.5.7. Sirtex (CDH)
  • 15.5.8. Johnson & Johnson
  • 15.5.9. Abbott Laboratories
  • 15.5.10. Balt Group

16. Strategic Recommendations

17. About Us & Disclaimer